Loss of PTEN expression is an independent poor prognostic factor in non-small cell lung cancer

Korean Journal of Pathology

Volumn 45, Issue 4, 2011, Pages 329-335

  Yoo, Seol Bong ^a   Xu, Xianhua ^a   Lee, Hyun Ju ^b,c   Jheon, Sanghoon ^a   Lee, Choon Taek ^a   Choe, Gheeyoung ^a   Chung, Jin Haeng ^a,c  

^a Seoul National University Bundang Hospital   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Carcinoma, non small cell; Immunohistochemistry; Prognosis; PTEN

Indexed keywords

EID: 80053016843     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2011.45.4.329     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Crystal AS, Shaw AT. New targets in advanced NSCLC: EML4-ALK. Clin Adv Hematol Oncol 2011; 9: 207-14.
3. Uramoto H, Shimokawa H, Hanagiri T, Kuwano M, Ono M. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer 2011; 73: 361-5.
4. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7.
5. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
6. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998; 7: 507-15.
7. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997; 57: 4183-6.
8. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002; 82: 285-91.
9. Marsit CJ, Zheng S, Aldape K, et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005; 36: 768-76.
10. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 2007; 96: 857-63.
11. Uramoto H, Sugio K, Oyama T, Sugaya M, Hanagiri T, Yasumoto K. Resistance to gefitinib. Int J Clin Oncol 2006; 11: 487-91.
12. Yamamoto C, Basaki Y, Kawahara A, et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70: 8715-25.
13. Yoo SB, Lee HJ, Park JO, et al. Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: a comparison with fluorescence in situ hybridization study. Lung Cancer 2010; 67: 301-5.
14. Travis W, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
15. Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007; 2: 686-93.
16. Chang YL, Wu CT, Lin SC, Hsiao CF, Jou YS, Lee YC. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin Cancer Res 2007; 13: 52-8.
17. Gallegos Ruiz MI, Floor K, Vos W, et al. Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization. Histopathology 2007; 51: 631-7.
18. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006; 51: 181-91.
19. Jiang Z, Wang X. Expression and significance of PTEN and nm23-H1 in the metastasis of non-small cell lung cancer.. Zhongguo Fei Ai Za Zhi 2008; 11: 793-7.
20. Lim WT, Zhang WH, Miller CR, et al. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep 2007; 17: 853-7.
21. Zhang H, Shu H, Jiang W. Expression of PTEN, p53 and P-glycoprotein in non-small cell lung cancer and their predictive values. Zhongguo Fei Ai Za Zhi 2009; 12: 1213-6.
22. Liao DW, Wang L, Zhang XG, Liu MQ. Expression and significance of PTEN/PI3K signal transduction-related proteins in non-small cell lung cancer. Ai Zheng 2006; 25: 1238-42.
23. Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol 2010; 5: 649-57.
24. Yamasaki F, Johansen MJ, Zhang D, et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007; 67: 5779-88.